IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. (Q53925120)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12838283

IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12838283

phase I clinical trial

0 references

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

Jeffrey S. Miller

11

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12838283

6

object named as

Blazar BR

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12838283

Angela Panoskaltsis-Mortari

8

object named as

Panoskaltsis-Mortari A

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12838283

author name string

Burns LJ

1

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12838283

Weisdorf DJ

2

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12838283

DeFor TE

3

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12838283

Vesole DH

4

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12838283

Repka TL

5

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12838283

Burger SR

7

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12838283

Keever-Taylor CA

9

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12838283

Zhang MJ

10

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12838283

language of work or name

0 references

publication date

1 July 2003

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12838283

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12838283

32

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12838283

2

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12838283

177-186

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12838283

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704086

0 references

A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

21 January 2018

Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

21 January 2018

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

21 January 2018

The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

21 January 2018

Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

21 January 2018

Amplification of immunological functions by subcutaneous injection of intermediate-high dose interleukin-2 for 2 years after autologous stem cell transplantation in children with stage IV neuroblastoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

21 January 2018

Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

21 January 2018

Autologous bone marrow versus non-mobilized peripheral blood stem cell transplantation for lymphoid malignancies: a prospective, comparative trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin 2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia--a phase I study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy with interleukin-2 and alpha-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

7 January 2021

based on heuristic

inferred from DOI database lookup

Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

7 January 2021

based on heuristic

inferred from DOI database lookup

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo cytokine responses to interleukin-2 immunotherapy after autologous stem cell transplantation in children with solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

7 January 2021

based on heuristic

inferred from DOI database lookup

Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

7 January 2021

based on heuristic

inferred from DOI database lookup

Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1704086

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12838283

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12838283

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53925120&oldid=1871148899"